|Last Price$104.83||Day Change (%)0.62%|
|Open Price$104.33||Day Change ($)0.65|
|Day Range103.73–106.27||52-Week Range63.50–116.83|
As of Fri 01/30/2015 08:06 PM EST | USD
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
MARKET SNAPSHOT: Gasoline 'Tax Cut' In Focus On Energy, Consumer-based Earnings
UPDATE: Gasoline 'tax cut' in focus on energy, consumer-based earnings
EnvisionRx and Gilead Sciences Sign Exclusive Agreement to Help in the Fight Against Hepatitis C
Gilead , CVS strike deal on Hepatitis C drugs
Gilead to buy liver disease treatment from Germany's Phenex
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
AbbVie Predicts Sharp Increase in Earnings
UPDATE: Are consumers getting gouged on health care?